Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study
暂无分享,去创建一个
C. Held | C. Cannon | K. Mahaffey | A. Siegbahn | L. Wallentin | P. Steg | S. James | R. Storey | D. Lindholm | A. Himmelmann | K. Gabrysch
[1] Søren B. Padkjær,et al. GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand , 2017, Nature Medicine.
[2] P. Emmerson,et al. The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL , 2017, Nature Medicine.
[3] T. Cash-Mason,et al. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates , 2017, Nature Medicine.
[4] C. Held,et al. Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease. , 2017, Journal of the American College of Cardiology.
[5] S. Yusuf,et al. Growth‐differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long‐Term Anticoagulation Therapy (RE‐LY) trial , 2017, American heart journal.
[6] C. Cannon,et al. Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding , 2017, Journal of the American Heart Association.
[7] C. Cannon,et al. Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome. , 2017, Clinical chemistry.
[8] C. Held,et al. Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease. , 2017, Clinical chemistry.
[9] J. Alfredsson,et al. Timing of percutaneous coronary intervention in patients with non-ST-elevation myocardial infarction: a SWEDEHEART study , 2017, European heart journal. Quality of care & clinical outcomes.
[10] S. Yusuf,et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study , 2016, The Lancet.
[11] E. Hagström,et al. Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. , 2016, European heart journal.
[12] Akshay S. Desai,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.
[13] M. Link,et al. B-type natriuretic peptide is a major predictor of ventricular tachyarrhythmias. , 2014, Heart rhythm.
[14] C. Held,et al. Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes , 2014, Heart.
[15] L. Lind,et al. GDF-15 for Prognostication of Cardiovascular and Cancer Morbidity and Mortality in Men , 2013, PloS one.
[16] L. Lind,et al. Change in growth differentiation factor 15 concentrations over time independently predicts mortality in community-dwelling elderly individuals. , 2013, Clinical chemistry.
[17] A. Zarbock,et al. GDF‐15 prevents platelet integrin activation and thrombus formation , 2013, Journal of thrombosis and haemostasis : JTH.
[18] Christiane,et al. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2013, JAMA.
[19] U. Haberkorn,et al. Growth Differentiation Factor‐15 Deficiency Inhibits Atherosclerosis Progression by Regulating Interleukin‐6–Dependent Inflammatory Response to Vascular Injury , 2012, Journal of the American Heart Association.
[20] Deepak L. Bhatt,et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. , 2012, The New England journal of medicine.
[21] L. Lind,et al. Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. , 2009, European heart journal.
[22] Claes Held,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.
[23] A. Skene,et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. , 2009, American heart journal.
[24] H. Oswald,et al. Comparison of N-terminal pro-brain natriuretic peptide versus electrophysiologic study for predicting future outcomes in patients with an implantable cardioverter defibrillator after myocardial infarction. , 2007, The American journal of cardiology.
[25] P. Poole‐Wilson,et al. Prognostic importance of plasma NT‐pro BNP in chronic heart failure in patients treated with a β‐blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) trial , 2007, European journal of heart failure.
[26] M. Pfeffer,et al. Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. , 2007, Journal of the American College of Cardiology.
[27] R. Califf,et al. Prognostic Value of Growth-Differentiation Factor-15 in Patients With Non–ST-Elevation Acute Coronary Syndrome , 2007, Circulation.
[28] K. Bibbins-Domingo,et al. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. , 2007, JAMA.
[29] R. Califf,et al. Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy. , 2006, Journal of the American College of Cardiology.
[30] L. Wallentin,et al. Admission N-terminal pro-brain natriuretic peptide and its interaction with admission troponin T and ST segment resolution for early risk stratification in ST elevation myocardial infarction , 2005, Heart.
[31] L. Køber,et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. , 2005, The New England journal of medicine.
[32] K. Unsicker,et al. Involvement of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in oxLDL-induced apoptosis of human macrophages in vitro and in arteriosclerotic lesions , 2004, Cell and Tissue Research.
[33] Wolzt,et al. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, The Journal of the American College of Dentists.
[34] M. Sabatine,et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. , 2001, The New England journal of medicine.